B Modell
Cystic fibrosis (CF), the commonest serious recessively inherited disease of Caucasians, is fast becoming preventable. The gene in which mutation can lead to CF, the cystic fibrosis transmembrane conductance regulator (CFTR), has recently been identified, and a deletion of three DNA base pairs that removes a phenylalanine residue from position 508 of the protein product accounts for 60 to 80% of CF mutations in the UK population.' This mutation can be detected by relatively simple DNA methods.2 3 Consequently, geneticists are now confronting an imminent need to set up population screening for CF carriers, a challenge that, if appropriately seized, could greatly improve the delivery of genetics services as a whole.
At present, clinical geneticists are mainly concerned with diagnosis, counselling, and prenatal diagnosis for families referred to them. Relatively few have yet been drawn into the issues of population screening and the outreach approach to the community that it entails. However, a recent report of the Royal College of Physicians (RCP)4 pointed out the existence of a range of 'community genetics services', that is, preventive genetics services based on population screening that are often delivered by obstetricians and others, rather than by clinical geneticists. They include (1) neonatal screening for phenylketonuria, congenital hypothyroidism, and other disorders; (2) screening in pregnancy for rhesus blood group and viral infections, maternal serum AFP screening, the offer of fetal karyotyping to older women, and midtrimester ultrasound scanning for fetal anomalies; (3) population screening for carriers of haemoglobin disorders or Tay-Sachs disease.
The RCP report noted many shortcomings in the delivery of these services and proposed that they When an inherited disease becomes preventable through carrier screening, it has been recommended to carry out studies in families detected retrospectively (with an affected child) as a first step, in order to assess acceptability, verify methodology, and identify problems among couples who are already well aware of the problem.7 In reality, the first stage has already been passed for cystic fibrosis, but as the results have not been systematically collected, we still lack the objective statistical information we need.
The acceptability of prenatal diagnosis is influenced by the accuracy, timing, and obstetric risk of the procedure as well as by the severity of the disorder. Prenatal diagnosis of CF was first achieved by assay of amniotic fluid enzymes at 18 to 20 weeks' gestation, with about a 5% false positive and false negative rate.8 The development of DNA methods based on linkage with restriction fragment length polymorphisms (RFLPs)9 introduced definitive carrier diagnosis, and moved prenatal diagnosis for CF back to the first trimester and increased its accuracy. However, some diagnoses still had to be confirmed by enzyme assay in the second trimester, and the obstetric risk of chorionic villus sampling was unknown.' As further linkages were established with even closer RFLPs" and the commonest mutation has been defined, reliable diagnosis has become possible for more and more families. In the meantime, the risk of CVS has been shown to be acceptably low. 12 As laboratory and obstetric methods have improved, the acceptability of prenatal diagnosis for CF is likely to have increased over the past five years.
We now urgently need to know the number of couples with affected children who have undertaken pregnancies since prenatal diagnosis became possible, the number that requested prenatal diagnosis, the method used, and the outcome. Experience of the haemoglobin disorders suggests that the behaviour of couples with affected children is a reasonable predictor of the behaviour of couples detected prospectively.7
Lessons from the Mediterranean experience with thalassaemia Screening will be required for the equivalent of at least one birth cohort of the population per year, but the real requirement will be at least twice as high because it will be necessary to promote several approaches to screening, and many relatives of the identified carriers will also wish to be screened. With about 700 000 births a year, the annual requirement in the UK will be for at least 1 5 to 2 million screening tests; about 70 000 carriers will be detected and require full information; and up to 1500 couples at risk will require counselling and the option of prenatal diagnosis. Such a large service will require careful planning.
Fortunately, the thalassaemia control programmes of southern Europe provide a provisional blueprint for developing a screening service for a common and serious recessively inherited disease. The Italian experience reported by the WHO' 1 provides the best model for the UK, because the populations of the two countries are similar in size and the birth incidence of thalassaemia major in Italy is similar to that of CF in the UK. The outstanding lessons are as follows.
(1) A screening programme is best organised on a regional basis. It requires the support of the Regional Health Authority. In the UK this means that a very good case will have to be presented, including costbenefit analysis and organisation of a monitoring system.
(2) A regional 'management group' including representatives of all the medical services involved, public health officials, and lay support associations is required. Support associations have a vitally important role in voicing the community's need for the service, in winning the support of the health authorities, and in informing the public.
(3) Reliable and adequate local services for carrier screening must be set up, and a quality control system is essential. (11) The delivery of services, both for patient care and for prevention, must be monitored. This can be done simply through a regional and national patient register updated annually.
Many of the general issues of genetic screening, including the need for a regional organisation, education, counselling, professional training, and monitoring, are covered in the RCP report. Here it seems appropriate to concentrate on the nature of the infrastructure that will be needed.
The infrastructure for screening It will be necessary to provide: (1) information to the population; (2) a system for collecting samples from a cohort of the population at some point before reproduction and delivering them to a laboratory; (3) a network of diagnostic laboratories with a quality control system; (4) a system for reporting the results to doctors and the people concerned; (5) an information storage and retrieval system; (6) information and counselling for carriers; (7) adequate expert centres for counselling couples at risk and providing prenatal diagnosis; and (8) a system for monitoringfhe service.
We are a long way from being able to meet these requirements. Some pilot projects should be started immediately to work out how an infrastructure can best be developed. Various systems can be envisaged. Screening might be offered to young people in schools, premaritally, as part of a service provided by GPs, in family planning clinics, in antenatal clinics, or by newborn screening.
Premarital testing is a disappearing target, as formal marriage is going out of fashion in much of Europe. Where it is the policy (in Greece and parts of Italy), most couples come for testing only when the woman is pregnant. Screening in high schools, offered for Tay-Sachs disease in Montreal'5 and for thalassaemia in Latium in Italy,16 may be a good strategy but it requires a well informed population and a developed infrastructure, and there is a long interval between testing and the use of the information.
It is only in the antenatal and newborn periods, pregnant women and newborn babies being 'captive' populations, that anything resembling the infrastructure necessary for screening yet exists. For practical reasons, it will be necessary to start CF screening at one of these two points.
What should be done now? There is no question that the new findings should be used at once for carrier and prenatal diagnosis for families detected retrospectively, and this is already under way. But should screening be started now and, if so, what strategy should be used?
Neonatal screening for CF using DNA methods would identify both affected and carrier infants, and the aim would be to follow up the parents of the latter to identify couples at risk. However, neonatal screening is a very inefficient way to identify couples at risk, because 50% will be missed: 25% will already have had an affected baby (and may not be happy when they realise this could have been avoided had screening been provided antenatally) and 25% will have a normal baby and so remain undetected. Neonatal screening seems quite unrealistic as an approach for identifying couples for reproductive counselling.
The idea of newborn screening seems attractive because screening for phenylketonuria and congenital hypothyroidism is already taking place. However, this service aims only to identify and refer relatively few infants with potentially serious conditions. Little 
